DBD vs RUN
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
DBD presents a stark dichotomy between explosive earnings growth and concerning sentiment indicators. With a Piotroski F-Score of 4/9, the company's financial health is categorized as stable but lacks strong momentum. While the stock currently trades at a premium to its Graham Number ($42.15) and Intrinsic Value ($74.93), the low forward P/E of 12.75 suggests the market is pricing in continued earnings acceleration. However, heavy insider liquidation and a bearish technical trend significantly offset the strong analyst 'strong_buy' consensus.
Sunrun Inc. exhibits severe financial instability, highlighted by a weak Piotroski F-Score of 2/9 and a high Debt/Equity ratio of 2.98. While the stock trades below its Graham Number ($22.71) and Book Value (P/B 0.92), these value metrics are offset by negative ROE (-22.06%) and a bearish technical trend. Massive revenue growth (123.5%) is currently decoupled from consistent profitability, and aggressive insider selling by the CEO, CFO, and President signals a lack of internal confidence.
Compare Another Pair
Related Comparisons
DBD vs RUN: Head-to-Head Comparison
This page compares Diebold Nixdorf, Incorporated (DBD) and Sunrun Inc. (RUN) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.